Industry News

Hims & Hers Announces Strategic Shift for US Weight Loss Business

In the US, the company now plans to provide GLP-1 customers with access to a broad assortment of FDA-approved medications.

Author Image

By: Lianna Albrizio

Associate Editor

Hims & Hers Health, Inc. is collaborating with Novo Nordisk as part of a new strategy for weight loss care treatments involving GLP-1s. The move evolves its US offering to match the company’s approach globally. In the US, the company now plans to provide GLP-1 customers with access to a broad assortment of FDA-approved medications and offer compounded semaglutide through the platform on a limited scale. By aligning its domestic and international models in weight loss, Hims & Hers w...

Continue reading this story and get 24/7 access to Happi for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Happi Newsletters

Topics